Semin Thromb Hemost 2015; 41(01): 001-006
DOI: 10.1055/s-0035-1544217
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Welcome to Seminars in Thrombosis & Hemostasis 2015: New (2013) Impact Factor and Most Highly Cited Articles

Emmanuel J. Favaloro
1  Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia
› Author Affiliations
Further Information

Publication History

Publication Date:
02 February 2015 (online)

Welcome to the start of another year with Seminars in Thrombosis & Hemostasis (STH). This is my 7th year as editor-in-chief, and my 10th year of editorial association with this journal, having originally served as a regional editor. First, I sincerely wish to thank all the contributors to STH over the past years, as well as the guest editors for these issues, and of course, the current and past senior and associate editors of the journal. There will be some changes to the editorial team over the forth coming 12 months, with an expansion of this team currently in plan. Also, Dr. Catherine Hayward has indicated she would like to step down from her role as senior editor. We sincerely thank her for her support in previous years and wish her continued success in her work. Last year represented a milestone for this journal, representing the 40th year of publication, a landmark that we celebrated with two special 40th anniversary celebratory issues.[1] [2]

I will also take this opportunity to thank the journal production team at Thieme Medical Publishers for their high production standards and for facilitating both the print and online issues of the journal. In particular, I would like to thank Subhankar De, the production editor for STH for managing the production process of STH issues and articles. I also wish to thank Kelly Coffey, a journals coordinator for Thieme Medical Publishers, as well as other key people at Thieme, some of who prefer to remain unnamed, for the additional support provided over the recent years.

This is also a fitting time to once again reflect on our journal's impact factor, which was 3.693 for 2013. This represents a drop from our 2012 impact factor of 4.216 ([Fig. 1]). I am hopeful that this pattern reflects some stabilization of the STH impact factor at around 4 over the coming years. It might be of some interest to note that the impact factor for most thrombosis and hemostasis focused journals fell in 2013 compared with 2012 values ([Fig. 2]). The reason for this generalized fall in impact factor for thrombosis and hemostasis focused journals is unknown, although it could be at least in part due to continued development of additional publishing avenues from open access models. I have also previously highlighted,[3] [4] and would continue to assert, that the impact factor is not the only marker of journal “quality” that we should consider, given the existence of other biometric markers and the limitations of any individual marker (including the impact factor) as a “quality” indicator.

Zoom Image
Fig. 1 The impact factor for Seminars in Thrombosis & Hemostasis, from 2003 to 2013.
Zoom Image
Fig. 2 The relative change in impact factor (IF) from 2012 to 2013 for eight thrombosis and hemostasis-focused journals. Data shown as IF change from 2012 to 2013 in absolute terms (left axis; gray bars) and as a percentage change (right axis; hatched bars). The data for Seminars in Thrombosis & Hemostasis identified as STH.

Nevertheless, for the potential interest of the readership and contributing authors, I have listed the highest 2013-cited, 2010/2011-published, contributions from this journal in [Table 1].[5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] These contributions identify those publications most contributing to the 2013 impact factor, and each was cited five or more times in 2013. The top 20-listed articles[5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] were each actually cited 10 or more times in 2013. For those interested, the current listing can be compared with those of the most recently published top downloaded article listings from STH, the basis of the Eberhard Mammen “Most Popular” awards.[63] [64] Accordingly, I thank all the contributors, guest editors, and the editorial team for bringing us the content that makes STH.

Table 1

Most highly (2013) cited (2010/2011-published) contributions from Seminars in Thrombosis & Hemostasis

  1. Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost 2012;38(6):565–575

  2. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 2012;38(2):178–184

  3. Allman-Farinelli MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011;37(8):903–907

  4. Ichinose A. Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost 2011;37(4):382–388

  5. Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012;38(4):375–384

  6. De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost 2011;37(3):226–236

  7. Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost 2012;38(2):200–212

  8. Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. Semin Thromb Hemost 2012;38(5):535–548

  9. Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost 2012;38(4):305–321

  10. Ballmaier M, Germeshausen M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost 2011;37(6):673–681

  11. Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost 2012;38(6):576–585

  12. Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost 2011;37(3):280–297

  13. Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost 2012;38(1):16–22

  14. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 2012;38(4):322–327

  15. Preissner KT, Reuning U. Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin Thromb Hemost 2011;37(4):408–424

  16. Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012;38(1):79–94

  17. Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost 2011;37(8):885–896

  18. Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012;38(5):433–446

  19. Nurden AT, Pillois X, Fiore M, Heilig R, Nurden P. Glanzmann thrombasthenia-like syndromes associated with Macrothrombocytopenias and mutations in the genes encoding the αIIbβ3 integrin. Semin Thromb Hemost 2011;37(6):698–706

  20. Plebani M, Favaloro EJ, Lippi G. Patient safety and quality in laboratory and hemostasis testing: a renewed loop? Semin Thromb Hemost 2012;38(6):553–558

  21. Lippi G, Cervellin G. Degradation of troponin I in serum or plasma: mechanisms, and analytical and clinical implications. Semin Thromb Hemost 2012;38(2):222–229

  22. Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011;37(5):440–455

  23. Maas C, Oschatz C, Renné T. The plasma contact system 2.0. Semin Thromb Hemost 2011;37(4):375–381

  24. Zeerleder S. C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost 2011;37(4):362–374

  25. Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost 2011;37(3):209–219

  26. Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitalented participants in intercellular communication. Semin Thromb Hemost 2012;38(1):102–113

  27. Di Fabio F, Lykoudis P, Gordon PH. Thromboembolism in inflammatory bowel disease: an insidious association requiring a high degree of vigilance. Semin Thromb Hemost 2011;37(3):220–225

  28. Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 2012;38(4):385–389

  29. Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II—Lupus anticoagulant. Semin Thromb Hemost 2012;38(4):404–411

  30. Blavignac J, Bunimov N, Rivard GE, Hayward CP. Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. Semin Thromb Hemost 2011;37(6):713–720

  31. Hampshire DJ, Goodeve AC. The international society on thrombosis and haematosis von Willebrand disease database: an update. Semin Thromb Hemost 2011;37(5):470–479

  32. Hayward CP, Moffat KA, Liu Y. Laboratory investigations for bleeding disorders. Semin Thromb Hemost 2012;38(7):742–752

  33. Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. Semin Thromb Hemost 2013;39(3):258–266

  34. Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. Semin Thromb Hemost 2011;37(3):237–251

  35. Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012;38(1):47–54

  36. Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. Semin Thromb Hemost 2012;38(4):360–374

  37. Targher G, Pichiri I, Lippi G. Vitamin D, thrombosis, and hemostasis: more than skin deep. Semin Thromb Hemost 2012;38(1):114–124

  38. Tufano A, Di Capua M, Coppola A, et al. The infectious burden in atherothrombosis. Semin Thromb Hemost 2012;38(5):515–523

  39. Sørensen B, Larsen OH, Rea CJ, Tang M, Foley JH, Fenger-Eriksen C. Fibrinogen as a hemostatic agent. Semin Thromb Hemost 2012;38(3):268–273

  40. Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. Semin Thromb Hemost 2012;38(5):506–514

  41. Kulkarni R, Soucie JM. Pediatric hemophilia: a review. Semin Thromb Hemost 2011;37(7):737–744

  42. Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. Semin Thromb Hemost 2011;37(3):252–266

  43. van der Post JA, Lok CA, Boer K, Sturk A, Sargent IL, Nieuwland R. The functions of microparticles in pre-eclampsia. Semin Thromb Hemost 2011;37(2):146–152

  44. Lockwood CJ, Huang SJ, Krikun G, et al. Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia. Semin Thromb Hemost 2011;37(2):158–164

  45. Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012;38(1):23–30

  46. Federici AB, Bucciarelli P, Castaman G, et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost 2011;37(5):511–521

  47. Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: part II. Semin Thromb Hemost 2012;38(5):447–453

  48. Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2012;38(5):483–496

  49. Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011;37(3):267–274

  50. Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost 2012;38(5):454–462

  51. Favaloro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RC. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I—Anticardiolipin and anti-β2-glycoprotein I antibodies. Semin Thromb Hemost 2012;38(4):390–403

  52. de Groot PG, Urbanus RT. The future of antiphospholipid antibody testing. Semin Thromb Hemost 2012;38(4):412–420

  53. Millikan PD, Balamohan SM, Raskind WH, Kacena MA. Inherited thrombocytopenia due to GATA-1 mutations. Semin Thromb Hemost 2011;37(6):682–689

  54. Howard BM, Daley AT, Cohen MJ. Prohemostatic interventions in trauma: resuscitation-associated coagulopathy, acute traumatic coagulopathy, hemostatic resuscitation, and other hemostatic interventions. Semin Thromb Hemost 2012;38(3):250–258

  55. Montagnana M, Meschi T, Borghi L, Lippi G. Thrombosis and occlusion of vascular access in hemodialyzed patients. Semin Thromb Hemost 2011;37(8):946–954

  56. Toriello HV. Thrombocytopenia-absent radius syndrome. Semin Thromb Hemost 2011;37(6):707–712

  57. Di Paola J, Johnson J. Thrombocytopenias due to gray platelet syndrome or THC2 mutations. Semin Thromb Hemost 2011;37(6):690–697

  58. 58. Lippi G, Franchini M, Cervellin G. Diagnosis and management of ischemic heart disease. Semin Thromb Hemost 2013;39(2):202–213

Finally, a short note to confirm that we will continue to develop plans for the future content of this journal, and we are confident that we will be able to continue to bring you, the reader, the high-quality journal that you have come to expect. Currently confirmed topics for issues that we plan to publish over the next 12 or so months are listed in [Table 2]. At the same time, we recognize the need to retain some flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises.

Table 2

Current planned topics for future issues of Seminars in Thrombosis and Hemostasis

  • Thrombosis and hemostasis issues in critically ill patients

  • Anticoagulant therapy: present and future

  • Current issues in hemophilia: recognizing clinical heterogeneity, replacement therapy, and outcome assessment

  • Tissue factor in arterial and venous thrombosis. From pathophysiology to clinical implications

  • Hemostatic dysfunction in liver diseases

  • Hot topics VII (continuing series)

  • Quality in thrombosis and hemostasis (continuing series)

We look forward to another interesting year of reading in 2015!